Want to join the conversation?
$AKAM 2Q15 PR: Revenue was up 14% YoverY to $540.72MM vs. $476.04MM in 2Q14. Net income was $67.20MM vs. $72.89MM in 2Q14. Diluted EPS was down 8% YoverY to $0.37 vs. $0.40 per share in 2Q14. Costs and operating expenses were $434.46MM vs. $363.68MM in 2Q14. Income from operations $106.26MM vs. $121.52MM in 2Q14.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?